Biologics in hidradenitis suppurativa: Progress and new directions
Journal of the American Academy of Dermatology · 2024-12 · 91 (6) · S27-S30
DOI: 10.1016/j.jaad.2024.09.027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2024-12. Verfasst von Alexandra Charrow und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham & Women's Hospital, Boston, Massachusetts. Electronic address: acha…. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Adalimumab, Biological Products, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
There are currently 2 Food and Drug Administration-approved treatments for hidradenitis suppurativa, and both are biologic medication -- Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha and Secukinumab, an interleukin-17A inhibitor. While both medications have demonstrated modest benefit in patients with hidradenitis suppurativa, patients may lose response over time and neither treatment works in all patients. This review outlines the use of these 2 Food and Drug Administration-approved treatments, the best timing of biologic therapy initiation, the evolving pipeline of biologic treatments, and how to best utilize therapeutic drug monitoring to increase the longevity of these critical treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham & Women's Hospital, Boston, Massachusetts. Electronic address: acharrow@bwh.harvard.edu.
- Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham & Women's Hospital, Boston, Massachusetts.
- Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Zitieren
APA
Charrow, A., Santiago-Soltero, K., & Porter, M. (2024). Biologics in hidradenitis suppurativa: Progress and new directions. Journal of the American Academy of Dermatology, 91(6), S27-S30. https://doi.org/10.1016/j.jaad.2024.09.027
Vancouver
Charrow A, Santiago-Soltero K, Porter M. Biologics in hidradenitis suppurativa: Progress and new directions. Journal of the American Academy of Dermatology. 2024;91(6):S27-S30. doi:10.1016/j.jaad.2024.09.027
BibTeX
@article{Charrow2024,
author = {Charrow, Alexandra and Santiago-Soltero, Karla and Porter, Martina},
title = {Biologics in hidradenitis suppurativa: Progress and new directions},
journal = {Journal of the American Academy of Dermatology},
year = {2024},
volume = {91},
number = {6},
pages = {S27--S30},
doi = {10.1016/j.jaad.2024.09.027}
}
EUVIMED